Individuals with early cognitive symptoms not reaching severity of dementia (CDR = 0.5) in combination with the presence of AD pathology, reaching an ABC-score of "Low" or "Intermediate" were considered as prodromal AD according to IWG-2 and AD-MCI according to NIA-AA criteria.
Furthermore, once the neurofibrillary pathology reaches the basal forebrain (occasionally already in Braak stage I), impaired retrograde transport of NGF could be the consequence, leading to an accumulation of NGF where it is synthesized (hippocampus and neocortex) and to a loss of NGF in the basal forebrain (Fig. 2).
Computer simulations predicted that qualitative changes in primary afferent excitability linked to neuropathic pain arise through a switch in spike initiation dynamics when molecular pathologies reach a tipping point (criticality), and that this tipping point can be reached via several different molecular pathologies (degeneracy).
It may be that once the disease pathology has reached a certain point, whatever neuroprotective effects testosterone may have had no longer exist, and the level of testosterone affects the likelihood of specific negative behaviors.
This change is mostly driven by the high-throughput scanning of microscope slides in modern pathology departments, reaching tens of thousands of digital slides per month.
Note that in Fig. 3B we do not intend to imply that subjects with mixed pathology necessarily reach a diagnosis of dementia at a younger age, but rather do so with a lower Aβ level than subjects with pure Alzheimer's pathology.
A consensus cancer diagnosis was reached by pathology.
However, the time from fixation until the tissue reached the pathology lab was less than 72 h, and we considered this to be an acceptable uniform handling of the tissue.
Antegrade access is more commonly used in patients with diabetes, where below-the-knee pathology can be more easily reached than through an over-the-bifurcation procedure.
13– 18 Despite excellent negative predictive values (NPV), the false negative rate (FNR) of SLNB for HNSCC (i.e. percentage of cases with overall positive END, SLN pathology-negative) appears variable and reached nearly 10%% in the two largest multicenter series.
